Clinical Trials

  • Sana Loue
  • Earl C. Pike


Tuberculosis Control Tuberculosis Disease Vaccine Trial Latent Tuberculosis Infection Clinical Equipoise 


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. Allen, M., Israel, H., Rybczyk, K. et al. (2001). Trial-related discrimination in HIV vaccine clinical trials. AIDS Research and Human Retroviruses, 17, 667–674.PubMedCrossRefGoogle Scholar
  2. American Medical Association, Council on Ethical and Judicial Affairs. (2000). Fee splitting: Referrals to health care facilities (Opinion E-603). In American Medical Association Council on Ethical and Judicial Affairs, Code of Medical Ethics: Current Opinions. Chicago, Illinois: Author.Google Scholar
  3. American Medical Association, Council on Ethical and Judicial Affairs. (1994). Finder’s Fees: Payment for the Referral of Patients to Clinical Research Studies (report #65). Chicago, Illinois: Author.Google Scholar
  4. Ananworanich, J., Cheunyam, T., Teeratakulpisarn, S., et al. (2004). Creation of a drug fund for post-clinical trial access to antiretrovirals. Lancet, 364, 101–102.PubMedCrossRefGoogle Scholar
  5. Angell, M. (1997). The ethics of clinical research in the Third World. New England Journal of Medicine, 337, 847–849.PubMedCrossRefGoogle Scholar
  6. Annas, G.J. & Grodin, M.A. (1998). Human rights and maternal-fetal HIV transmission prevention trials in Africa. American Journal of Public Health, 88(4), 560–563.PubMedGoogle Scholar
  7. Armistead, L.P., Clark, H., Barber, C.N., Dorsey, S., Hughley, J., Favors, M., & Wyckoff, S.C. (2004). Participant retention in the Parents Matter! Program: Strategies and out-come. Journal of Child and Family Studies, 13(1), 67–80.CrossRefGoogle Scholar
  8. Bayer, R. (1998). The debate over maternal-fetal HIV transmission prevention trials in Africa, Asia, and the Caribbean: Racist exploitation or exploitation of racism? American Journal of Public Health, 88(4), 567–570.PubMedCrossRefGoogle Scholar
  9. Bloom, B.R. (1998). The highest attainable standard: Ethical issues in AIDS vaccines. Science, 279 (5348), 186–188.Google Scholar
  10. Bodenheimer, T. (2000). Uneasy alliance: Clinical investigators and the pharmaceutical industry. New England Journal of Medicine, 342, 1539–1543.PubMedCrossRefGoogle Scholar
  11. Canadian HIV/AIDS Legal Network. (2002). HIV Vaccines in Canada: Legal and Ethical Issues. An Overview. Toronto, Canada: Author.Google Scholar
  12. Caschetta, M.B., Chavkin, W., & McGovern, T. (1993). FDA policy on women in drug trials [correspondence]. New England Journal of Medicine, 329, 1815.PubMedCrossRefGoogle Scholar
  13. Chow, S.C. & Liu, J-P. (2003). Design and Analysis of Clinical Trials: Concepts and Methodologies. Hoboken, New Jersey: John Wiley & Sons, Inc.Google Scholar
  14. Collins, A. & Baumgartner, D. (1995). U.S. prisoners’ access to experimental HIV thera-pies. Minnesota Medicine, 78(11), 45–48.PubMedGoogle Scholar
  15. Connor, E.M., Sperling, R.S., Gelber, R., et al. (1994). Reduction of maternal-infant trans-mission of HIV type I with ZDV treatment. New England Journal of Medicine, 331, 1173–1180.PubMedCrossRefGoogle Scholar
  16. Council of International Organizations for Medical Sciences. (2002). International Ethical Guidelines for Biomedical Research Involving Human Subjects. Geneva, Switzerland: Author.Google Scholar
  17. Crouch, R.A. & Arras, J.D. (1998). AZT trials and tribulations. Hastings Center Report, 28(6), 26–34.PubMedCrossRefGoogle Scholar
  18. Daunt, D.J. (2003). Ethnicity and recruitment rates in clinical research studies. Applied Nursing Research, 16(3), 189–195.PubMedCrossRefGoogle Scholar
  19. De Zoysa, I., Elias, C.J., & Bentley, M.E. (1998). Ethical challenges in efficacy trials of vaginal microbicides for HIV prevention. American Journal of Public Health, 88(4), 571–575.PubMedGoogle Scholar
  20. De Zulueta, P. (2001). Randomised placebo-controlled trials in HIV-infected pregnant women in developing countries. Ethical imperialism or unethical exploitation? Bioethics, 15(4), 289–311.PubMedCrossRefGoogle Scholar
  21. DeAngelis, C.D. (2001). Conflict of interest and the public trust [editorial]. Journal of the American Medical Association, 284, 2237–2238.CrossRefGoogle Scholar
  22. DeVesa, F. (1993). Opinion letter from Attorney General of New Jersey to Commissioner W.H. Fauver, New Jersey Department of Corrections, November 30. Cited in G.L. Stein & L.D. Headley. (1996). Forum on prisoners’ access to clinical trials: Summary of recommendations. AIDS & Public Policy Journal, 11(1), 3–20.Google Scholar
  23. Edi-Osagie, E.C.O. & Edi-Osagie, N.E. (1998). Placebo trials are unethical for estab-lished, untested treatments. British Medical Journal, 316, 625.Google Scholar
  24. Faden, R. & Kass, N. (1998). HIV research, ethics, and the developing world [editorial]. American Journal of Public Health, 88(4), 548–550.PubMedGoogle Scholar
  25. Family Health Research Group. (1998). The Family Health Project: A multidisciplinary longitudinal investigation of children whose mothers are HIV-infected. Clinical Psychology Review, 18, 839–856.CrossRefGoogle Scholar
  26. Feinberg, J. & Japour, A.J. (2003). Scientific and ethical considerations in trial design for investigational agents for the treatment of human immunodeficiency virus. Clinical Infectious Diseases, 36, 201–206.PubMedCrossRefGoogle Scholar
  27. Food and Drug Administration. (1998). Information Sheets: Guidance for Institutional Review Boards and Clinical Investigators. Rockville, Maryland: Author.Google Scholar
  28. Freedman, B. (1991). Suspended judgment: AIDS and the ethics of clinical trials: Learning the right lessons. Controlled Clinical Trials, 13(1), 1–5.CrossRefGoogle Scholar
  29. Frey, S.E. (2003). Unique risks to volunteers in HIV vaccine trials. Journal of Investigative Medicine, 51 (Supp. 1), S18-S20.PubMedGoogle Scholar
  30. Grosskurth, H., Mosha, F., Todd, J. et al. (1995). Impact of improved treatment of sexually transmitted diseases on HIV infection in rural Tanzania: Randomized controlled trial. Lancet, 346, 530–536.PubMedCrossRefGoogle Scholar
  31. Habiba, M. & Evans, M. (2002). The inter-role confidentiality conflict in recruitment for clinical research. The Journal of Medicine and Philosophy, 27(5), 565–587.PubMedCrossRefGoogle Scholar
  32. Halsey, N.A., Sommer, A., & Black, R.E. (1998). Authors’ reply. British Medical Journal, 316, 627.Google Scholar
  33. Heckerling, P.S. (2005). The ethics of single-blind trials. IRB: Ethics & Human Research, 27(4), 12–16.Google Scholar
  34. Henderson, J.A. & Smith, J.J. (2002). Financial conflict of interest in medical research: Overview and analysis of federal and state controls. Food and Drug Law Journal, March, 1–11.Google Scholar
  35. Homer, C.S.E. (2002). Using the Zelen design in randomized controlled trials: Debates and controversies. Journal of Advanced Nursing, 38(2), 200–207.PubMedCrossRefGoogle Scholar
  36. Iltis, A.S. (2005). Timing invitations to participate in clinical research: Preliminary versus informed consent. Journal of Medicine and Philosophy, 30, 89–106.PubMedCrossRefGoogle Scholar
  37. Institute of Medical Ethics Working Party on the Ethical Implications of AIDS. (1992). British Medical Journal, 305, 699–701.Google Scholar
  38. Kaiser, J. (1997). Bangkok study adds fuel to AIDS ethics debate. Science, 278 (5343), 1553.PubMedGoogle Scholar
  39. Kass, N.E., Taylor, H.A., & King, P.A. (1996). Harms of excluding pregnant women from clinical research: The case of HIV-infected pregnant women. Journal of Law, Medicine & Ethics, 24, 36–46.CrossRefGoogle Scholar
  40. Kent, D.M., Mwamburi, M., Cash, R.A., Tabin, T.L., & Bennish, M.L. (2003). Testing therapies less effective than the best current standard: Ethical beliefs in an international sample of researchers. American Journal of Bioethics, 3(2), W28-W33.CrossRefGoogle Scholar
  41. Killen, J., Grady, C., Folkers, G.K., & Fauci, A.S. (2002). Ethics of clinical research in the developing world. Nature Reviews, 2, 210–215.PubMedCrossRefGoogle Scholar
  42. Kodish, E., Lantos, J.D., & Siegler, M. (1990). Ethical considerations in randomized controlled clinical trials. Cancer, 65 (Suppl.), 2400–2404.PubMedCrossRefGoogle Scholar
  43. Korn, D. (2000). Conflicts of interest in biomedical research. Journal of the American Medical Association, 284, 2234–2237.PubMedCrossRefGoogle Scholar
  44. Last, J.M. (Ed.) (1988). A Dictionary of Epidemiology, 2nd ed. New York: Oxford University Press.Google Scholar
  45. Lemmens, T. & Miller, P.B. (2003). The human subjects trade: Ethical and legal issues surrounding recruitment incentives. Journal of Law, Medicine & Ethics, 31, 398–418.CrossRefGoogle Scholar
  46. Levine, R.J. (1985). The use of placebos in randomized controlled clinical trials. IRB: A Review of Human Subjects Research, 7, 1–6.Google Scholar
  47. Lo, B., Wolf, L.E., & Berkeley, A. (2000). Conflict-of-interest policies for investigators in clinical trials. New England Journal of Medicine, 343, 1616–1620.PubMedCrossRefGoogle Scholar
  48. Loue, S., Lurie, P., & Lloyd, L.S. (1995). Ethical issues raised by needle exchange programs. Journal of Law, Medicine, and Ethics, 23(4), 382–388.PubMedCrossRefGoogle Scholar
  49. Loue, S., Okello, D., & Kawuma, M. (1996). Research bioethics in the Ugandan context. Journal of Law, Medicine, and Ethics, 24(1), 47–53.PubMedCrossRefGoogle Scholar
  50. Lurie, P., Bishaw, M., Chesney, M.A. et al. (1994). Ethical, behavioral, and social aspects of HIV vaccine trials in developing countries. Journal of the American Medical Association, 271(4), 295–301.PubMedCrossRefGoogle Scholar
  51. Lurie, P. & Wolfe, S.M. (1997). Unethical trials of interventions to reduce perinatal transmis-sion of human immunodeficiency virus in developing countries. New England Journal of Medicine, 337, 853–856.PubMedCrossRefGoogle Scholar
  52. Macklin, R. & Friedland, G. (1986). AIDS research: The ethics of clinical trials. Law, Medicine & Health Care, 14(5–6), 273–280.Google Scholar
  53. Meinert, C.L. (1986). Clinical Trials: Design, Conduct, and Analysis. New York: Oxford University Press.Google Scholar
  54. Moodley, K. (2002). HIV vaccine trial participation in South Africa—An ethical assessment. Journal of Medicine and Philosophy, 27(2), 197–215.PubMedCrossRefGoogle Scholar
  55. Moore v. Regents of the University of California. (1990). 793 P.2d 479, cert. denied, 499 U.S. 936 (1991).Google Scholar
  56. Mugerwa, R.D., Kaleebu, P., Mugyenyi, P. et al. (2002). First trial of the HIV-1 vaccine in Africa: Ugandan experience. British Medical Journal, 324, 226–229.PubMedCrossRefGoogle Scholar
  57. Muthuswamy, V. (2005). Ethical issues in HIV/AIDS research. Indian Journal of Medical Research, 121, 601–610.PubMedGoogle Scholar
  58. Nairn, T.A. (1993). The use of Zairian children in HIV vaccine experimentation: A cross-cultural study in medical ethics. The Annual of the Society of Christian Ethics, 13, 223–243.Google Scholar
  59. National Commission for the Protection of Human Subjects. (1979). The Belmont Report. Washington, D.C.: United States Department of Health and Human Services.Google Scholar
  60. National Institutes of Health. (2005). An Introduction to Clinical trials. Available at Last accessed August 14, 2006.Google Scholar
  61. Pasquerella, L. (2002). Confining choices: Should inmates’ participation in research be limited? Theoretical Medicine, 23, 519–536.CrossRefGoogle Scholar
  62. Porter, J.D.H., Forrest, B.D., & Kennedy, A.R. (1992). The ethics of placebos in AIDS drug trials. Healthcare Ethics Committee Forum, 4(3), 155–162.Google Scholar
  63. Resnik, D.B. (2003). Exploitation in biomedical research. Theoretical Medicine, 24, 233–259.CrossRefGoogle Scholar
  64. Roe v. Fauver. (1992). Consent decree. C.A. No. 88–1225-AET (D. New Jersey, March 3).Google Scholar
  65. Schüklenk, U. (1998). Unethical perinatal HIV transmission trials establish bad precedent. Bioethics, 12, 312–319.PubMedCrossRefGoogle Scholar
  66. Sheon, A.R., Wagner, L., McElrath, M.J. et al. (1998). Preventing discrimination against volunteers in prophylactic HIV vaccine trials: Lessons learned from a phase II trial. Journal of Acquired Immune Deficiency Syndromes and Human Retrovirology, 19, 519–526,PubMedGoogle Scholar
  67. Simberkoff, M.S., Hamilton, J.D., Gail, M. et al. (1993). Ethical dilemmas in continuing a zidovudine trial after early termination of similar trials. Controlled Clinical Trials, 14(1), 6–18.PubMedCrossRefGoogle Scholar
  68. Stein, G.L. & Headley, L.D. (1996). Forum on prisoners’ access to clinical trials: Summary of recommendations. AIDS & Public Policy Journal, 11(1), 3–20.Google Scholar
  69. Stein, R.E. (1994). Vaccine liability and participant compensation incentives in HIV vaccine trials. AIDS Research and Human Retroviruses, 10(Supp. 2), S297-S300.Google Scholar
  70. Stone, V.E., Steger, K.A., Hirschorn, L.R. et al. (1998). Access to treatment with protease inhibitor containing regimens: Is it equal for all? Presented at the 12th International AIDS Conference, Geneva, Switzerland, June 28-July 3 [abstract no. 42305].Google Scholar
  71. Trials of War Criminals before the Nuremberg Military Tribunals under Control Council Law No. 10, Vol. 2 (pp. 181–182). Nuremberg October 1946 – April 1949, Washington. U.S. Government Printing Office (n.d.).Google Scholar
  72. UNAIDS. (2000). Ethical Considerations in HIV Preventive Vaccine Research: UNAIDS Guidance Document. Geneva, Switzerland: Joint United Nations Programme on AIDS. Available at Scholar
  73. Varmus, H. & Satcher, D. (1997). Ethical complexities of conducting research in develop-ing countries. New England Journal of Medicine, 337(14), 1003–1005.PubMedCrossRefGoogle Scholar
  74. Veatch, R.M. (1989). Drug research in humans: The ethics of nonrandomized access. Clinical Pharmacy, 8(5), 366–370.PubMedGoogle Scholar
  75. Wadman, M. (1996). Drug company “suppressed” publication of research. Nature, 381(6577), 4.PubMedGoogle Scholar
  76. World Medical Association. (1964). Declaration of Helsinki.Google Scholar
  77. World Medical Association. (1996, 2002). Declaration of Helsinki.Google Scholar
  78. Writing Committee. (1999). Science, ethics, and the future of research into maternal infant transmission of HIV-1. Lancet, 353, 832–835.Google Scholar
  79. Zelen, M. (1979). A new design for randomized controlled trials. New England Journal of Medicine, 300, 1242–1245.PubMedCrossRefGoogle Scholar
  80. Zelen, M. (1990). Strategy and alternative designs for clinical trials: An update. Statistics in Medicine, 9, 645–656.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2007

Authors and Affiliations

  • Sana Loue
    • 1
  • Earl C. Pike
    • 2
  1. 1.Case Western Reserve UniversityCleveland
  2. 2.AIDS Taskforce of Greater ClevelandCleveland

Personalised recommendations